Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Geron Corporation
Geron Corporation News
Dec 11, 2025 - globenewswire.com
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Dec 8, 2025 - globenewswire.com
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
Geron Corporation Quantitative Score
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Geron Corporation Financials
Table Compare
Compare GERN metrics with: | |||
|---|---|---|---|
Earnings & Growth | GERN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GERN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GERN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GERN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Geron Corporation Income
Geron Corporation Balance Sheet
Geron Corporation Cash Flow
Geron Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Geron Corporation Executives
| Name | Role |
|---|---|
| Ms. Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer |
| Mr. Scott Samuels | Executive Vice President, Chief Legal Officer & Secretary |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| Ms. Dawn Schottlandt CFA | Senior Vice President of Investor Relations & Corporate Affairs |
| Mr. Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | Female | 1967 | 846.38K |
| Mr. Scott Samuels | Executive Vice President, Chief Legal Officer & Secretary | Male | 485.32K | |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research & Development and Chief Medical Officer | 1967 | 304.1K | |
| Ms. Dawn Schottlandt CFA | Senior Vice President of Investor Relations & Corporate Affairs | Female | -- | |
| Mr. Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | Male | -- |
Geron Corporation Insider Trades
| Date | 20 Oct |
| Name | ElNawawi Ahmed |
| Role | EVP, Chief Commercial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 3000000 |
| Date | 20 Oct |
| Name | ElNawawi Ahmed |
| Role | EVP, Chief Commercial Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 30 Sep |
| Name | Spiegel Robert J. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5702 |
| Date | 7 Aug |
| Name | Semerjian Harout |
| Role | President and CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7000000 |
| Date | 7 Aug |
| Name | Semerjian Harout |
| Role | President and CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 4000000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 20 Oct | ElNawawi Ahmed | EVP, Chief Commercial Officer | Acquired | A-Award | 3000000 |
| 20 Oct | ElNawawi Ahmed | EVP, Chief Commercial Officer | Disposed | 0 | |
| 30 Sep | Spiegel Robert J. | Director | Acquired | A-Award | 5702 |
| 7 Aug | Semerjian Harout | President and CEO | Acquired | A-Award | 7000000 |
| 7 Aug | Semerjian Harout | President and CEO | Acquired | A-Award | 4000000 |